Viking Therapeutics, Inc. (VKTX) Financials
VKTX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 368.5 million | 20.1 million |
| 2023-09-30 | 382.7 million | 14.4 million |
| 2023-06-30 | 400.7 million | 14.6 million |
| 2023-03-31 | 150.9 million | 16.8 million |
VKTX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -17.6 million | 4.1 million |
| 2023-09-30 | -19.7 million | 4.5 million |
| 2023-06-30 | -11.4 million | 4.6 million |
| 2023-03-31 | -24.6 million | 3.6 million |
VKTX Net Income
No data available :(
VKTX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 362.1 million | - | 1.3 million |
| 2023-09-30 | 376.2 million | - | 1.3 million |
| 2023-06-30 | 392.9 million | - | 1.4 million |
| 2023-03-31 | 135.7 million | - | 1.5 million |
VKTX Shares Outstanding
VKTX Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | - | 20.5 million | 8.8 million | - |
| 2023-09-30 | - | 18.4 million | 8.9 million | - |
| 2023-06-30 | - | 13.9 million | 9.8 million | - |
| 2023-03-31 | - | 11.0 million | 9.5 million | - |
VKTX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | - | 74000 |
| 2023-09-30 | - | 73000 |
| 2023-06-30 | - | 73000 |
| 2023-03-31 | - | 72000 |
VKTX
Price: $76.97
52 week price:
Earnings Per Share: -0.91 USD
P/E Ratio: -30.41
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.7 million
Ebitda: -4.7 millionMarket Capitalization: 8.2 billion